Mutation T315I - Chronic Myeloid Leukemia- CML
CLINICAL TRIAL DRUGS
AP24534 - Ponatinib by Ariad
Omacetaxine by ChemGenex
DCC-2036 and DCC- 2157 by Deciphera
KW-2449 by Kyowa Hakko Kirin Pharma, Inc
AP24534 - Ponatinib by Ariad
Omacetaxine by ChemGenex
DCC-2036 and DCC- 2157 by Deciphera
KW-2449 by Kyowa Hakko Kirin Pharma, Inc
AACR 2012: Promising CML & PI3K compounds from Indian company Piramal Healthcare (P2745 - T315i mutation)
April 24, 2012,Biotech Strategy Blog
Novel potent inhibitor (P2745) of Bcr-Abl mutated imatinib resistant chronic myeloid leukemia cell lines (included
T315I)
April 2, 2012, AACR Annual Meeting 2012
T315I)
April 2, 2012, AACR Annual Meeting 2012
Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa.
January 20, 2012, International Journal of Hematology
A clinical Trial ( Mutation T315I) and a Growing Family - Hans Loland VIDEO
November 18, 2011, Patient Power
Treatment of chronic phase (CP) chronic myeloid leukemia (CML) patients who harbour the BCR-ABL T315I mutation with subcutaneous omacetaxine results in improved survival compared to historical data
June 12 2011, EHA 2011
A pyrosequencing-based test for detection and relative quantification of the BCR-ABL1 T315I point mutation
April 12, 2011, Journal of clinical pathology
Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036
April 12, 2011, Cancer cell
Ariad, MolecularMD To Develop Diagnostic Test For CML Patients
April 6, 2011, Clinical Lab Products
Ariad, MolecularMD Partner on Companion Dx for T315I Mutation
March 28, 2011, genomeweb
Phase I Trial Shows Ponatinib May Thwart Most Resistant CML
December 16, 2010, MD Anderson Cancer Center - Department of Leukemia
Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia
November 17, 2010, Clinical Cancer Research
The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile
November 15, 2010, Cancer Research
KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutatedBCR/ABL translocation
May 28, 2009, Journal Blood
ChemGenex's Omacetaxine Demonstrates 80% Complete Hematological Response Rate In Drug-Resistant CML Patients With The T315I Mutation
December 10, 2008, Medical News Today
Complete Suppression of in Vitro Resistance by AP24534, a Pan-BCR-ABL Inhibitor
December 8, 2008, ASH2008
Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia
March 6, 2008, Clinical Cancer Research
January 20, 2012, International Journal of Hematology
A clinical Trial ( Mutation T315I) and a Growing Family - Hans Loland VIDEO
November 18, 2011, Patient Power
Treatment of chronic phase (CP) chronic myeloid leukemia (CML) patients who harbour the BCR-ABL T315I mutation with subcutaneous omacetaxine results in improved survival compared to historical data
June 12 2011, EHA 2011
A pyrosequencing-based test for detection and relative quantification of the BCR-ABL1 T315I point mutation
April 12, 2011, Journal of clinical pathology
Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036
April 12, 2011, Cancer cell
Ariad, MolecularMD To Develop Diagnostic Test For CML Patients
April 6, 2011, Clinical Lab Products
Ariad, MolecularMD Partner on Companion Dx for T315I Mutation
March 28, 2011, genomeweb
Phase I Trial Shows Ponatinib May Thwart Most Resistant CML
December 16, 2010, MD Anderson Cancer Center - Department of Leukemia
Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia
November 17, 2010, Clinical Cancer Research
The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile
November 15, 2010, Cancer Research
KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutatedBCR/ABL translocation
May 28, 2009, Journal Blood
ChemGenex's Omacetaxine Demonstrates 80% Complete Hematological Response Rate In Drug-Resistant CML Patients With The T315I Mutation
December 10, 2008, Medical News Today
Complete Suppression of in Vitro Resistance by AP24534, a Pan-BCR-ABL Inhibitor
December 8, 2008, ASH2008
Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia
March 6, 2008, Clinical Cancer Research
